# EDGAR Filing Document

**Accession Number:** 0001178879
**File Stem:** 0001104659-25-056821
**Filing Date:** 2025-6
**Character Count:** 6492
**Document Hash:** 99e0fbd7b9f729e5c9a3aa2443709e46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-056821.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001104659-25-056821

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250605

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMICUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001178879
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 200422823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33497
- **FILM NUMBER:** 251027014

**BUSINESS ADDRESS:**
- **STREET 1:** 47 HULFISH STREET
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08542
- **BUSINESS PHONE:** (609) 662-2000

**MAIL ADDRESS:**
- **STREET 1:** 47 HULFISH STREET
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08542

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMICUS THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20020729

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO**

**SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **June 5, 2025**

**AMICUS THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| Delaware | 001-33497 | 71-0869350 |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission<br> File Number)** | **(I.R.S. Employer<br> Identification No.)** |

---

47 Hulfish Street, Princeton, New Jersey 08542

**(Address of Principal Executive Offices, and Zip Code)**

609-662-2000

**Registrant's Telephone Number, Including Area Code**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock Par Value $0.01 | FOLD | NASDAQ |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 - Submission of Matters to a Vote of Security Holders.**

At the 2025 Annual Meeting of Stockholders of the Company, held on June 5, 2025, the Company's stockholders elected Michael A. Kelly, Margaret G. McGlynn, Michael G. Raab and Glenn P. Sblendorio as Class III directors to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the 2025 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and (iii) approved, on an advisory basis, the compensation paid to the Company's named executive officers. The final voting results on these matters were as follows:

**1.** Election of Directors.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Nominee | Votes For | Votes For | Votes Withheld | Votes Withheld | Broker Non-Votes | Broker Non-Votes |
| Michael A. Kelly |  | 256542874 |  | 5972321 |  | 20343283 |
| Margaret G. McGlynn |  | 253119576 |  | 9395619 |  | 20343283 |
| Michael G. Raab |  | 159986932 |  | 102528263 |  | 20343283 |
| Glenn P. Sblendorio |  | 255741822 |  | 6773373 |  | 20343283 |

---

**2.** Approval of the 2025 Equity Incentive Plan.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Votes For | Votes For | Votes Against | Votes Against | Votes Abstain | Votes Abstain | Broker Non-Votes | Broker Non-Votes |
|  | 253118014 |  | 8908436 |  | 488745 |  | 20343283 |

---

**3.** Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Votes For | Votes For | Votes Against | Votes Against | Votes Abstain | Votes Abstain | Broker Non-Votes |
|  | 277786618 |  | 5006701 |  | 65159 |  |

---

**4.** Approval, on an advisory basis, of the Company's executive compensation.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Votes For | Votes For | Votes Against | Votes Against | Votes Abstain | Votes Abstain | Broker Non-Votes | Broker Non-Votes |
|  | 255789585 |  | 6169769 |  | 555841 |  | 20343283 |

---

**Item 9.01 Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits:**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**<u>Signature Page</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AMICUS THERAPEUTICS, INC. | AMICUS THERAPEUTICS, INC. |
| Date: June 5, 2025 | By: | /s/ Ellen S. Rosenberg |
|  | Name: | Ellen S. Rosenberg |
|  | Title: | Chief Legal Officer and Corporate Secretary |

---